HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

methyl carbamate

Also Known As:
carbamic acid, methyl ester
Networked: 16 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Youdim, Moussa B H: 4 articles (04/2012 - 10/2002)
2. Bar-Am, Orit: 4 articles (04/2012 - 10/2002)
3. Amit, Tamar: 4 articles (04/2012 - 10/2002)
4. Weinreb, Orly: 2 articles (04/2012 - 01/2010)
5. Keifer, Matthew: 2 articles (11/2010 - 01/2002)
6. Wesseling, Catharina: 2 articles (11/2010 - 01/2002)
7. Yogev-Falach, Merav: 2 articles (05/2003 - 10/2002)
8. Weinstock, Marta: 2 articles (05/2003 - 10/2002)
9. Kawakami, Masato: 1 article (06/2014)
10. Fuwa, Haruhiko: 1 article (06/2014)

Related Diseases

1. HIV Infections (HIV Infection)
2. Dementia (Dementias)
3. Intracranial Arteriosclerosis (Cerebral Atherosclerosis)
4. Basal Ganglia Diseases (Basal Ganglia Disease)
5. Alzheimer Disease (Alzheimer's Disease)
10/01/2002 - "Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)-ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). "
05/01/2003 - "Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326 and TV3279 [(N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate], respectively were derived from rasagiline, for the treatment of Alzheimer's disease (AD). "
12/01/2001 - "Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. "
01/01/2010 - "This indication and recent therapeutic approaches, entailing new drug candidates possessing diverse pharmacological properties and acting on multiple targets, have stimulated the development of two multifunctional chimeric propargylamine-derivatives: 1) ladostigil (TV3326, [(N-propargyl-(3R) 1-(R)-aminoindan-5yl)-ethyl methyl carbamate)], which combines the pharmacophore of rasagiline, with the carbamate moiety of the cholinesterase inhibitor rivastigmine, as a potential treatment for Alzheimer's disease and Lewy body disease; and 2) M30 5-[(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline], where the propargylamine moiety of rasagiline was embedded onto the backbone of the neuroprotective and brain permeable iron chelator 8-hydroxyquinoline-derivative, VK28 as a potential treatment for various neurodegenerative disorders. "

Related Drugs and Biologics

1. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate
2. N-propargyl
3. HIV Protease
4. Monoamine Oxidase (MAO)
5. Carbon Monoxide
6. Acetylcholine (Acetylcholine Chloride)
7. Cholinesterases (Cholinesterase)
8. rasagiline (Azilect)
9. (N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate
10. Monoterpenes